Physician profile

Umar M Osman

Pulmonary Disease · Greenwood, IN

NPI 1487882635

$19,277.00

in general payments reported to CMS, 2019-2025

43 companies · $217 in 2025

The $217 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$865.96

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $6,654.35 2019-2021
Astrazeneca Pharmaceuticals Lp $2,143.50 2019-2024 Fasenra, Airsupra
Glaxosmithkline, LLC. $1,704.49 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $934.27 2019-2025 Jascayd, Spiriva Respimat, Stiolto Respimat
Pulmonx Corporation $790.99 2019-2021
Boston Scientific Corporation $753.63 2019
Bard Access Systems, INC. $603.18 2019
Merck Sharp & Dohme LLC $541.90 2019-2020
Olympus Corporation of The Americas $450.67 2019
Insmed, INC. $424.01 2019-2022
Regeneron Healthcare Solutions, INC. $388.10 2019-2023 Dupixent
Mallinckrodt Hospital Products INC. $311.15 2020-2021
Grifols USA, LLC $306.02 2019-2024 Prolastin-C Liquid
Genentech USA, INC. $301.13 2019-2021
United Therapeutics Corporation $277.50 2019-2021
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Jazz Pharmaceuticals INC. $250.55 2019-2020
Chiesi USA, INC. $249.91 2019-2021
Genzyme Corporation $242.84 2020-2025
Mallinckrodt Enterprises LLC $200.74 2019
Paratek Pharmaceuticals, INC. $176.69 2019-2022
Takeda Pharmaceuticals U.S.A., INC. $175.59 2020-2024 Glassia
Electromed, INC. $170.01 2019-2025 Smartvest
Alexion Pharmaceuticals, INC. $158.96 2019
Astellas Pharma US INC $132.18 2019-2020
Pfizer INC. $126.45 2020-2023
Bard Peripheral Vascular, INC. $120.25 2019
Philips North America LLC $120.01 2019-2023
Advanced Respiratory, INC $76.32 2019-2020
Actelion Pharmaceuticals US, INC. $67.00 2021-2025 Opsumit, Uptravi
Novartis Pharmaceuticals Corporation $56.79 2019-2022
Harmony Biosciences LLC $52.28 2024-2025
Teva Pharmaceuticals USA, INC. $49.56 2021-2022
Sunovion Pharmaceuticals INC. $49.28 2019-2020
Resmed Corp $31.50 2019
Shire North American Group INC $28.52 2019
Baxter Healthcare $28.25 2023 Hillrom - Monarch Airway Clearance System
Mayne Pharma Commercial LLC $23.09 2020
Biogen, INC. $21.70 2021
Avadel Cns Pharmaceuticals, LLC $20.32 2024 Lumryz
Nestle Healthcare Nutrition INC. $17.70 2021
Circassia INC. $16.33 2019
Gilead Sciences, INC. $14.78 2021
Seqirus USA INC $14.51 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Umar M Osman

$19,277.00

in general payments reported 2019-2025

Years
2019-2025
Top company
Mylan Specialty L.P.
Context
The $217 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/405411/umar-m-osman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.